Vedantra Pharmaceuticals, Inc. — Form D/A

Vedantra Pharmaceuticals, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2022-11-02. The offering totals $50.0M, of which $22.0M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (25)

NameRoleLocation
Julian AdamsDirectorBoston, MA
Carol AsheDirectorBoston, MA
Yekaterina ChudnovskyDirectorLOS ANGELES, CA
Robert ConnellyDirectorBoston, MA
Daniel GeffkenDirectorBoston, MA
Daphne KarydasDirectorBrooklyn, NY
Robert RuffoloDirectorBoston, MA
Assaf SegalDirectorBoston, MA
Robert ConnellyExecutive OfficerBoston, MA
Daniel GeffkenExecutive OfficerBoston, MA
Christopher HaqqExecutive OfficerBoston, MA
Annette MatthiesExecutive OfficerBoston, MA
Julian AdamsExecutive OfficerBoston, MA
Daniel BehrDirectorWestborough, MA
Ofer GonenDirectorYavne, L3
Isaac KohlbergDirectorCambridge, MA
Frank HaluskaDirectorCambridge, MA
Isaac BlechDirectorJupiter, FL
William KosterDirectorWestborough, MA
Satish JindalDirectorCleveland, OH
Ben BronsteinDirectorWestborough, MA
Alan ShawDirectorCambridge, MA
Alan ShawExecutive OfficerCambridge, MA
Alan ShawPromoterCambridge, MA
Steve DeitcherDirectorCambridge, MA

Other filings by this issuer (12)

FiledFormOfferingSold
2022-05-27D$50.0M$975K
2021-11-18D/A$15.0M$14.5M
2021-11-12D/A$15.0M$14.5M
2021-10-19D$15.0M$2.0M
2020-07-15D$30.0M$6.1M
2020-03-13D$8.4M$8.4M
2019-10-15D$7.0M$7.0M
2018-09-14D$36.2M$25.8M
2018-08-03D$14.5M$14.5M
2018-06-05D$3.0M$3.0M
2016-05-24D$1.5M$750K
2012-07-31D$5.0M$3.3M

More